In addition, women were even less likely to receive high-efficacy treatments such as natalizumab, anti-CD20 antibodies, or ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that could impact long-term health outcomes for women of ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that ...

Fanapt, approved for bipolar I disorder, faces significant competition from generics like Abilify, making it unlikely to drive substantial revenue growth. Ponvory, acquired from Janssen, faces ...